# Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52‐week, open‐label, phase 3 study (<scp>UNCOVER</scp>‐J)

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/efficacy-and-safety-of-ixekizumab-treatment-for-japanese-patients-with-moderate/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Hidehisa Saeki,Hidemi Nakagawa,Ko Nakajo,Taeko Ishii,Yoji Morisaki,Takehiro Aoki,Gregory S. Cameron,Olawale Osuntokun,the Japanese Ixekizumab Study Group |
| Citations | 195 |
| DOI | 10.1111/1346-8138.13622 |
| Fields | Immunology and Microbiology,Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1346-8138.13622 |
| OpenAlex ID | https://openalex.org/W2530872160 |
| PMID | 27726163 |
| Type | article |
| Year | 2016 |

## Paper authors

- [Hidehisa Saeki](https://scholariq.org/researchers/hidehisa-saeki/)

## Paper journal

- [The Journal of Dermatology](https://scholariq.org/journals/the-journal-of-dermatology/)

## Paper primary topic

- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)

## Paper topics

- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Autoimmune Bullous Skin Diseases](https://scholariq.org/topics/autoimmune-bullous-skin-diseases/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.